Biogen expects Q2 IPR&D charge of ~$164M ($0.95/share) and Q3 charge of $290M-$320M ($1.75-$1.95/share)

BIOGEN INC.

Q2 2026: ~$164M pre-tax IPR&D charge; EPS impact ~$0.95 per share.
Q3 2026: $290M-$320M pre-tax IPR&D charge; EPS impact $1.75-$1.95 per share.
Charges relate to collaboration and license agreements, including upfront and milestone payments.
Results for Q2 2026 not finalized; subject to financial closing procedures.
Company does not forecast such expenses due to uncertainty of future transactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.